Kytopen reposted this
March was an exciting month for the next-generation therapeutics field. In the Cell Therapy space, NKGen Biotech, Inc. announced positive data for their autologous NK cell therapy, while a CAR-T cell product produced dramatic responses in patients with glioblastoma in a preliminary clinical trial at Mass General Cancer Center. Kytopen also announced their technology access program for their Flowfect platform, while Fiocruz and Caring Cross teamed up to manufacture CAR-T cells at a lower cost. In the ADC space, new partnerships were announced this past month, including Biocytogen’s collaboration with ABL Bio Inc. to develop bispecific ADCs and Biotheus Inc. expanding their collaboration with Jiangsu Hansoh Pharmaceutical Group Co., Ltd.. BrickBio, Inc. also announced compelling preclinical data showing complete tumor eradication in animal models treated with Pyrrolobenzodiazepine, while Bio-Thera Solutions received IND clearance for a Phase II study with BAT8006. In the Gene Therapy space, Nanoscope Therapeutics Inc. announced positive data for MCO-010 in vision loss, while Sangamo Therapeutics, Inc. announced exciting data with their AAV capsid variant STAC-BBB and Tenaya Therapeutics reported positive preclinical data for TN-401 in a rare heart condition. Charles River Laboratories and Navega Therapeutics also announced their partnership to expand manufacturing capabilities for the AAV gene therapy candidate NT-Z001. In the Oligo Therapy space, Silence Therapeutics plc announced positive data from a Phase 2 study with Zerlasiran in patients with high lipoprotein(a), while Moderna’s next-generation COVID vaccine achieved a higher immune response in a Phase 3 clinical trial. Capstan Therapeutics announced that they secured $175 million in a Series B financing round, while Blackstone announced their collaboration with Moderna, in which they will provide up to $750 million for mRNA-based influenza vaccines. Read on to see additional developments that occurred in March here: https://lnkd.in/gkxeDHNq Subscribe to our newsletter on Linkedin: https://lnkd.in/gMfy6_YZ Sign up to receive our Next-Generation Therapeutics Newsletter in your email: https://lnkd.in/gKQn7_zp These headlines were curated by Rebecca Burnham, PhD, Joe Daccache, Ph.D., Luka Jelcic, Juilee Malavade, Ph.D., and Carl Schoellhammer. #precisionmedicine #nextgenerationtherapeutics #celltherapy #genetherapy #oligotherapy #antibodydrugconjugates #decibio #innovation #biotechnology
VP of Commercial at DeciBio | Precision Medicine Strategy, Market Intelligence, Venture | BLOC, HBA
6moAwesome job on this March round up to the team Rebecca Burnham, PhD, Joe Daccache, Ph.D., Luka Jelcic, Juilee Malavade, Ph.D., and Carl Schoellhammer!